Atara Biotherapeutics Inc (NASDAQ: ATRA) stock enjoyed a major increase of 19.8% on 11/4/24. The shares closed at $11.63. Moreover, this advance was accompanied by unusually high trading volume at 194% of normal. The stock has risen 35.2% during the last week but has been extremely weak relative to the market over the last nine months.
Current PriceTarget Research Rating
With future capital returns forecasted to be in line with the cost of capital, ATRA is expected to continue to be Value Creation neutral.
Atara Biotherapeutics is currently unrated.
Rating Review
The stock is currently unrated.
Be the first to comment